Thursday 4 June 2020 ,
Thursday 4 June 2020 ,
Latest News
  • Bangladesh reports 2,423 new coronavirus cases, 35 deaths in 24hrs
  • Chinese medical expert team to arrive on June 8
  • Govt sincere to protect people from coronavirus: PM
  • Bangladesh's global partners urged to practise responsible business conduct
  • Global coronavirus death toll reaches 385, 873
  • Protesters welcome new charges in Floyd killing but remain in streets
  • PM narrates in Guardian article how Bangladesh fought twin perils of Covid-19 and cyclone
  • Number of coronavirus infected policemen rises to 5,507
  • Coronavirus Hotline Numbers: 01944333222, 16263, 333; website: www.corona.gov.bd
16 September, 2019 00:00 00 AM
Print

Full chemo doses may improve survival in breast cancer

HealthDay
Full chemo doses may improve survival in breast cancer

Maintaining full doses of chemotherapy, especially early in the treatment course, is important for survival of intermediate or high-risk breast cancer patients, according to a study published in the August issue of the Journal of the National Comprehensive Cancer Network.

Zachary Veitch, M.D., from the University of Calgary in Canada, and colleagues evaluated the impact of chemotherapy total cumulative dose (TCD), and early (5-fluorouracil/epirubicin/ cyclophosphamide) versus late (docetaxel only) dose reductions, on survival outcomes among women with stage I to III, hormone receptor-positive/negative, human epidermal growth factor receptor 2 -negative breast cancer treated with adjuvant 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel chemotherapy (from 2007 through 2014).

The researchers noted that 1,302 patients were evaluated for dose reductions, with 16 percent being reduced <85 percent (202 patients) versus ≥85 percent (1,100 patients; 84 percent). Compared to patients receiving <85 percent, those who received TCD ≥85 percent had superior five-year disease-free survival (DFS) and overall survival (OS). DFS and OS were significantly lower for patients with dose reduction early in treatment versus late in treatment.

Findings were similar in multivariate analyses (hazard ratios, 1.46 and 1.77, respectively). There was no effect on outcomes for dose delays of <14 or ≥14 days and granulocyte colony-stimulating factor.

"Often the first cycle of chemotherapy can be difficult for patients, and oncologists must convey the need for maintaining initial dose intensity, while using other medications to control side effects and manage comorbidities," Veitch said in a statement.

 

Comments

Most Viewed
Digital Edition
Archive
SunMonTueWedThuFri Sat
010203040506
07080910111213
14151617181920
21222324252627
282930

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting